Ibritumomab tiuxetan

Drug Profile

Ibritumomab tiuxetan

Alternative Names: 111In-ibritumomab tiuxetan; BAY86-5128; IDEC-129; IDEC-In2B8; IDEC-Y2B8; Indium-111 Ibritumomab tiuxetan; Monoclonal antibody IDEC-Y2B8; SH-L-749; Yttrium-90 ibritumomab tiuxetan; Zevalin; Zevamab

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Bayer Yakuhin; Biogen; Biogen Idec; CASI Pharmaceuticals; Dana-Farber Cancer Institute; Schering Korea; Spectrum Pharmaceuticals; Tufts-New England Medical Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action CD20 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Phase II MALT lymphoma; Multiple myeloma
  • No development reported Diffuse large B cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 12 Oct 2016 Spectrum Pharmaceuticals and myTomorrows enter into promotion agreement for ibritumomab tiuxetan in Europe
  • 11 Jan 2016 Servier in-licenses ibritumomab tiuxetan from Spectrum Pharmaceuticals in Canada
  • 08 Dec 2015 Spectrum Pharmaceuticals completes a phase II trial in Non-Hodgkin's lymphoma (First-line therapy) in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top